John Brassil (Kerry, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

420. To ask the Minister for Health when the freestyle libre system (details supplied) of blood testing will become available on the Irish market; if the HSE has plans to provide the technology on the long-term illness scheme; and if he will make a statement on the matter. [39438/16]

Marc MacSharry (Sligo-Leitrim, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

426. To ask the Minister for Health the reason the free style libre device (details supplied) for type 1 diabetes patients is not currently covered on the list of eligible items for the medical card or long term illness scheme; if his attention has been drawn to the impact of this blood sugar monitoring system on type 2 diabetes patients, particularly children; if he will include this in items covered by the medical card and long-term illness scheme; and if he will make a statement on the matter. [39511/16]

Kathleen Funchion (Carlow-Kilkenny, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

460. To ask the Minister for Health if his attention has been drawn to the new technology for young children with diabetes, the freestyle libre (details supplied); if he will consider investing in this technology to improve blood sugar control in young diabetics; and if he and the HSE will consider approving the freestyle libre on the long-term illness scheme. [39747/16]

John Curran (Dublin Mid West, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

519. To ask the Minister for Health if he will consider providing access to the freestyle libre, a blood sugar level meter for children with type 1 diabetes, on the long-term illness scheme; and if he will make a statement on the matter. [40060/16]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 420, 426, 460 and 519 together.

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicinal devices under the community drug schemes in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013.

The manufacturer must make a completed application to the HSE for reimbursement of the device under the Community Drugs Schemes. A health technology assessment may then be required to assess its clinical benefits and cost-effectiveness.